Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 11.24 percent increase over losses of $(0.89) per share from the same period last year.
Evercore ISI Group Downgrades Douglas Emmett to In-Line, Lowers Price Target to $24
Evercore ISI Group analyst Steve Sakwa downgrades Douglas Emmett (NYSE:DEI) from Outperform to In-Line and lowers the price target from $27 to $24.
